Combigene AB (COMBI) - Total Liabilities
Based on the latest financial reports, Combigene AB (COMBI) has total liabilities worth Skr4.30 Million SEK (≈ $462.75K USD) as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Combigene AB - Total Liabilities Trend (2012–2024)
This chart illustrates how Combigene AB's total liabilities have evolved over time, based on quarterly financial data. See working capital position of Combigene AB to evaluate short-term liquidity relative to the company's equity base.
Combigene AB Competitors by Total Liabilities
The table below lists competitors of Combigene AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Innity Corporation Bhd
KLSE:0147
|
Malaysia | RM39.63 Million |
|
ARK Resources Bhd
KLSE:7007
|
Malaysia | RM59.30 Million |
|
CF Energy Corp
V:CFY
|
Canada | CA$849.83 Million |
|
CaliberCos Inc. Class A Common Stock
NASDAQ:CWD
|
USA | $109.17 Million |
|
TV Thunder Public Company Limited
BK:TVT
|
Thailand | ฿27.59 Million |
|
Merino & Co. Ltd
AU:MNC
|
Australia | AU$4.50 Million |
|
Custodian REIT PLC
LSE:CREI
|
UK | GBX191.19 Million |
Liability Composition Analysis (2012–2024)
This chart breaks down Combigene AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Combigene AB stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 17.47 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Combigene AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Combigene AB (2012–2024)
The table below shows the annual total liabilities of Combigene AB from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr4.30 Million ≈ $462.75K |
+3.47% |
| 2023-12-31 | Skr4.16 Million ≈ $447.22K |
-31.86% |
| 2022-12-31 | Skr6.10 Million ≈ $656.32K |
-23.21% |
| 2021-12-31 | Skr7.94 Million ≈ $854.68K |
-0.49% |
| 2020-12-31 | Skr7.98 Million ≈ $858.87K |
-66.06% |
| 2019-12-31 | Skr23.51 Million ≈ $2.53 Million |
+60.38% |
| 2018-12-31 | Skr14.66 Million ≈ $1.58 Million |
+801.06% |
| 2017-12-31 | Skr1.63 Million ≈ $175.10K |
+100.96% |
| 2016-12-31 | Skr809.66K ≈ $87.13K |
+17.05% |
| 2015-12-31 | Skr691.73K ≈ $74.44K |
+18.85% |
| 2014-12-31 | Skr582.04K ≈ $62.64K |
+1320.21% |
| 2013-12-31 | Skr40.98K ≈ $4.41K |
-86.18% |
| 2012-12-31 | Skr296.58K ≈ $31.92K |
-- |
About Combigene AB
CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The… Read more